This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Sonus Could Soar on Drug Results

BOSTON -- Sonus Pharmaceuticals (SNUS) is nearing a make-or-break milestone for its experimental cancer drug.

The small Seattle-based biotech firm is preparing to release top-line results from a pivotal phase III study of Tocosol paclitaxel, a reformulation of the broadly used chemotherapy drug paclitaxel, which is known by its brand name Taxol.

Sonus' management has indicated that the phase III data should be ready at the end of September, so we're a month away from what should be a significant stock-moving catalyst.

I called this a make-or-break moment for Sonus -- and I mean it. At its Monday closing price of $3.85, Sonus shares could double if its drug is a success. A failure, of course, will send Sonus shares tumbling. The company has about $1.20 a share in cash.

The Sonus story is fairly straightforward: The company has developed a proprietary drug delivery technology using vitamin E that allows chemotherapy drugs to be administered much more easily, with less toxicity and fewer side effects. Superior efficacy is also a possibility.

Tocosol paclitaxel, or TocP, can be administered to a patient in 15 minutes, compared to the three-hour infusion time for normal Taxol. TocP also doesn't require patients to be pretreated with steroids either, like Taxol does.

Sonus' drug should also be less toxic than ordinary Taxol, most importantly with regard to neuropathy, a side effect affecting a patient's peripheral nerves that can cause tingling, numbness and pain.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs